modified IL-7 / Bright Peak Therap - LARVOL DELTA

Versant Ventures Launches Bright Peak Therapeutics (Businesswire) - "Versant Ventures...announced the debut of Bright Peak Therapeutics...Versant has made a $35 million Series A commitment to the company, which was launched out of the firm’s Ridgeline Therapeutics Discovery Engine based in Basel, Switzerland...The company has validated the platform by creating a portfolio of designer cytokines with the potential to be advanced as novel immune-oncology therapeutics...A pipeline was developed within Versant’s Ridgeline labs in collaboration with ETH Zürich. This included modified versions of IL-2, IL-18 and IL-7 optimized for the desired biology and pharmacokinetic profiles...Bright Peak is currently running IND-enabling studies and has launched scale-up and CMC campaigns on the first IL-2 development candidate with the expectation of entering the clinic within a year."

Commercial • Pipeline update • Oncology